Advertisement
UK markets open in 3 hours 24 minutes
  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     
  • HANG SENG

    17,626.00
    +341.46 (+1.98%)
     
  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD FUTURES

    2,344.70
    +2.20 (+0.09%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,502.47
    +8.48 (+0.02%)
     
  • CMC Crypto 200

    1,391.68
    +9.11 (+0.66%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

What Analysts Recommend for Merck and AstraZeneca in June

What Analysts Recommend for Merck and AstraZeneca in June

Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.